In this report, we present evidence that in the triple-negative breast cancer cells studied, all necessary steps of the GPR30 signaling are activated in response to 17β-estradiol and 4-hydroxytamoxifen. The gene discussed is GPER1; the disease is triple-negative breast carcinoma.